Prescription of targeted therapies for stage III colon cancer should consider renal function. Studies have not shown a benefit of bevacizumab or cetuximab in combination with chemotherapy. The prognostic importance of RAS and BRAF V600E mutations is established for stage III. Starting adjuvant chemotherapy more than 8 weeks after tumor resection may increase the risk of death. Other factors, such as post-operative complications, also impact prognosis.